AGIO:NASDAQ
Agios Pharmaceuticals Inc
37,18 $
arrow_upward
+1,47%(+0,54) 1D
37,18 $
0,00% (0,00)
bedtimeAfter hours
Closed: 21 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
36,62 $
High
37,58 $
Low
36,46 $
Mkt. cap
2,22 մլրդ
Avg. vol.
1,17 մլն
Volume
849,89 հզր
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,01 $
Beta
0,63
Shares outstanding
59,70 մլն
No. of employees
540
Open
36,62 $
High
37,58 $
Low
36,46 $
Mkt. cap
2,22 մլրդ
Avg. vol.
1,17 մլն
Volume
849,89 հզր
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,01 $
Beta
0,63
Shares outstanding
59,70 մլն
No. of employees
540
News stories
From web sources and news partners
Investing.com Australia
·
4 ժամ առաջ
Form 144 AGIOS PHARMACEUTICALS For: 21 October By Investing.com
Kalkine Media
·
4 ժամ առաջ
Agios Pharmaceuticals Officer Sarah Gheuens Files Form 144 to Sell 1,489 Shares via Stock Option Exercise
Zacks
·
11 ժամ առաջ
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Stock Traders Daily
·
1 օր առաջ
(AGIO) Price Dynamics and Execution-Aware Positioning
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc